Assembly Biosciences (ASMB) Equity Average (2016 - 2025)
Assembly Biosciences (ASMB) has 11 years of Equity Average data on record, last reported at $100.4 million in Q3 2025.
- For Q3 2025, Equity Average rose 230.88% year-over-year to $100.4 million; the TTM value through Sep 2025 reached $100.4 million, up 230.88%, while the annual FY2024 figure was $37.2 million, 39.84% down from the prior year.
- Equity Average reached $100.4 million in Q3 2025 per ASMB's latest filing, up from $22.6 million in the prior quarter.
- Across five years, Equity Average topped out at $243.9 million in Q1 2021 and bottomed at $22.6 million in Q2 2025.
- Average Equity Average over 5 years is $101.1 million, with a median of $76.5 million recorded in 2023.
- Peak YoY movement for Equity Average: plummeted 57.3% in 2023, then soared 230.88% in 2025.
- A 5-year view of Equity Average shows it stood at $196.8 million in 2021, then crashed by 52.98% to $92.5 million in 2022, then plummeted by 55.25% to $41.4 million in 2023, then dropped by 28.32% to $29.7 million in 2024, then surged by 238.26% to $100.4 million in 2025.
- Per Business Quant database, its latest 3 readings for Equity Average were $100.4 million in Q3 2025, $22.6 million in Q2 2025, and $30.2 million in Q1 2025.